Pre-made Narsoplimab benchmark antibody ( Whole mAb, anti-MASP2 therapeutic antibody, Anti-MAP-2/MAP19/MASP-2/MASP1P1/sMAP Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Narsoplimab biosimilar, Whole mAb, Anti-MASP2 Antibody: Anti-MAP-2/MAP19/MASP-2/MASP1P1/sMAP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Narsoplimab is the company's lead inhibitor of mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-366-1mg	1mg	3090
GMP-Bios-ab-366-10mg	10mg	Inquiry
GMP-Bios-ab-366-100mg	100mg	Inquiry
GMP-Bios-ab-366-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Narsoplimab biosimilar, Whole mAb, Anti-MASP2 Antibody: Anti-MAP-2/MAP19/MASP-2/MASP1P1/sMAP therapeutic antibody
INN Name	Narsoplimab
Target	MASP2
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Preregistration
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Omeros
Conditions Approved	na
Conditions Active	Haemolytic uraemic syndrome;IgA nephropathy;Immediate hypersensitivity;Thrombotic microangiopathies;Glomerulonephritis;Lupus nephritis;Membranous glomerulonephritis
Conditions Discontinued	Stroke;Wet age-related macular degeneration
Development Tech	na